ANTX vs APRE

AN2 Therapeutics, Inc. vs Aprea Therapeutics, Inc. — Valuation Comparison 2026

ANTX

Biotechnology
AN2 Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$4.46
Last close
Models
7/13
Active
VS

APRE

Biotechnology
Aprea Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$0.93
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ANTX Fair ValueANTX Upside APRE Fair ValueAPRE Upside
Bayesian DCF Intrinsic $2.01 -55.0% $2.30 +147.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.38 -91.4% $0.80 -14.3%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANTX vs APRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANTX vs APRE — Which Stock Is More Undervalued?

APRE scores higher with a 4.5/10 quality rating vs ANTX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AN2 Therapeutics, Inc. (ANTX) and Aprea Therapeutics, Inc. (APRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANTX currently trades at $4.46 with a QOC of 4.3/10, while APRE trades at $0.93 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).